FORA Capital’s RAPT Therapeutics RAPT Stock Holding History

FORA Capital’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-712	Closed	-$181K	–	751
2021 Q2	$181K	Buy	+712	New	+$133K	0.03%	468

Other funds holding RAPT

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

KXA

KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FORA Capital's RAPT Position: Q3 2021 in Review

FORA Capital sold out of RAPT Therapeutics (RAPT) in Q3 2021, closing a stake of 712 shares — an estimated $181K sold.

FORA Capital first reported a position in RAPT in Q2 2021 and held it in 1 quarter. The position peaked at $181K in Q2 2021. 106 funds tracked by Wall St. Rank hold RAPT as of Q3 2021.

FORA Capital reported no remaining RAPT Therapeutics position as of Q3 2021 after selling out during the quarter.
FORA Capital sold 712 RAPT Therapeutics shares in Q3 2021, an estimated $181K.
FORA Capital first reported a position in RAPT Therapeutics in Q2 2021 and held it in 1 quarter.
FORA Capital's RAPT Therapeutics position peaked at $181K in Q2 2021.
106 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q3 2021.

Based on FORA Capital's 13F filing for Q3 2021, filed 15 Nov 2021.